Holen Sie sich die Stockscreener-App
0.0127
3.05%
-0.0004
Handel nachbörslich:
.01
-0.0027
-21.26%
Schlusskurs vom Vortag:
$0.0131
Offen:
$0.0127
24-Stunden-Volumen:
328
Relative Volume:
0.85
Marktkapitalisierung:
$N/A
Einnahmen:
-
Nettoeinkommen (Verlust:
$-22.65M
KGV:
-0.00245
EPS:
-5.1849
Netto-Cashflow:
$-22.84M
1W Leistung:
-3.05%
1M Leistung:
+0.00%
6M Leistung:
+3.25%
1J Leistung:
-99.66%
1-Tages-Spanne:
$0.0127
$0.0127
1-Wochen-Bereich:
$0.0127
$0.0127
52-Wochen-Spanne:
$0.0101
$0.041
Vincerx Pharma Inc Stock (VINC) Company Profile
Firmenname
Vincerx Pharma Inc
Sektor
Branche
Telefon
-
Adresse
-
Compare VINC vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VINC
Vincerx Pharma Inc
|
0.0127 | 0 | 0 | -22.65M | -22.84M | -5.1849 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 116.49B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.73B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 55.49B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.75B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 33.54B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vincerx Pharma Inc Stock (VINC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-01-14 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-12-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-11-01 | Eingeleitet | SVB Leerink | Outperform |
| 2021-09-13 | Eingeleitet | Laidlaw | Buy |
| 2021-08-25 | Eingeleitet | B. Riley Securities | Buy |
Vincerx Pharma Inc Aktie (VINC) Neueste Nachrichten
Why Is Vincerx Pharma, Inc. (VINCU) Stock Down Today? - Meyka
Drug Transport Company Sued by Insurer Over Destroyed-Cells Case - Bloomberg Law News
VINC Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Head to Head Comparison: Ampio Pharmaceuticals (NYSE:AMPE) & Vincerx Pharma (NASDAQ:VINC) - Defense World
Contrasting Vincerx Pharma (NASDAQ:VINC) and iBio (NYSE:IBIO) - Defense World
Critical Review: Vincerx Pharma (NASDAQ:VINC) & Trevena (NASDAQ:TRVN) - Defense World
Reviewing Leap Therapeutics (NASDAQ:LPTX) and Vincerx Pharma (NASDAQ:VINC) - Defense World
Analyzing Vincerx Pharma (NASDAQ:VINC) & Petros Pharmaceuticals (NASDAQ:PTPI) - Defense World
Head to Head Analysis: Vectura Group (OTCMKTS:VEGPF) and Vincerx Pharma (NASDAQ:VINC) - Defense World
Vincerx Pharma, Inc. Announces Additional Adjournment of - GlobeNewswire
Vincerx Pharma, Inc. Urges Stockholders to Vote FOR Approval of Dissolution Proposal and Announces Potential Range for Distributions to Stockholders - The Manila Times
Vincerx Pharma | DEFA14A: Others - Moomoo
Global Digital Holdings Inc. cancelled the acquisition of Vincerx Pharma, Inc. in a reverse merger transaction. - marketscreener.com
VINC: Vincerx Pharma to dissolve, with minimal or no distributions expected for stockholders - TradingView
VINC Stock Price, News & Analysis - Stock Titan
VINC Stock Price and Chart — OTC:VINC - TradingView
VINC stock touches 52-week low at $0.17 amid sharp annual decline - Investing.com
Nasdaq to delist Vincerx Pharma by April 23 - Investing.com Australia
Vincerx Pharma Announces Complete Liquidation and Nasdaq Exit: What Happens to Your Shares? - Stock Titan
vincerx pharma cancels merger, initiates wind-down activities By Investing.com - Investing.com India
vincerx pharma cancels merger, initiates wind-down activities - Investing.com
Vincerx prepares to wind down as final merger attempt collapses - Fierce Biotech
Financially struggling drugmaker's potential rescue falls apart. It now will wind down - The Business Journals
Vincerx Pharma Inc. (VINC) reports earnings - qz.com
Vincerx, left in limbo by collapsed deal, moves to merge with AI company to escape cash crisis - Fierce Biotech
Cash-strapped Vincerx left mulling future after Oqory reverse merger falls apart - Fierce Biotech
Vincerx Pharma Announces Termination of Reverse Merger Term Sheet and Evaluation of Strategic Alternatives - Yahoo Finance
Vincerx Pharma, Oqory highlight Phase 1a/1b data for OQY-3258 - TipRanks
Vincerx Pharma, Inc. Announces 1-for-20 Reverse Stock Split Effective January 27, 2025 - Nasdaq
Vincerx Pharma, Inc. Announces Reverse Stock Split - The Manila Times
Vincerx Pharma enters at-the-market equity offering deal - Investing.com
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates VINC, MHLD, NEUE on Behalf of Shareholders - Finansavisen
Chutes & Ladders—Vincerx acquisition leads to C-suite shake-up - Fierce Biotech
Fierce Biotech Layoff Tracker 2024: Vincerx reduces workforce; Novartis lays off 330 staffers - Fierce Biotech
Vincerx Pharma Stock Rises On Proposed Merger With Oqory: Retail Remains Bullish - Asianet Newsable
Vincerx Pharma Enters into a Binding Term Sheet for a Strategic Merger with Oqory, Inc. - Yahoo Finance
Vincerx Pharma Stock Gets Retail Followers Buzzing With Big Layoff Plans To Sustain Cancer Drug Trials - Asianet Newsable
ARMISTICE CAPITAL, LLC Expands Stake in Vincerx Pharma Inc - GuruFocus
Prosight Management, LP Reduces Stake in Vincerx Pharma Inc - GuruFocus
Vincerx Pharma Inc (VINC) Quarterly 10-Q Report - qz.com
What Makes Vincerx Pharma (VINC) a New Buy Stock - Yahoo Finance
VINC Stock Touches 52-Week Low at $0.51 Amid Market Challenges - Investing.com
Vincerx Reports Positive Initial Clinical Data from Ongoing - GlobeNewswire
Vincerx Pharma (NASDAQ: VINCU)Share Price - intelligentinvestor.com.au
Vincerx Pharma Reports Second Quarter 2024 Financial Results - GlobeNewswire
Vincerx Pharma Announces Proposed Underwritten Public Offering of Common Stock and Warrants - Investing News Network
Vincerx Pharma Announces Pricing of Underwritten Public Offering of Common Stock and Warrants - Investing News Network
Vincerx Pharma Announces Proposed Underwritten Public Offering of Common Stock and Warrants By Investing.com - Investing.com India
Vincerx Blames Stock Plunge On Overheated ADC Expectations - Citeline News & Insights
Why Is Vincerx Pharma (VINC) Stock Down 64% Today? - InvestorPlace
Vincerx Pharma Presents Positive Preliminary Phase 1 Data - GlobeNewswire
Finanzdaten der Vincerx Pharma Inc-Aktie (VINC)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.74%
1.44%
Kapitalisierung:
|
Volumen (24h):